Cell Biochemistry and Biophysics

, Volume 61, Issue 2, pp 389–392 | Cite as

CD4 + CD25high Regulatory T Cell Numbers and FOXP3 mRNA Expression in Patients with Advanced Esophageal Cancer Before and After Chemotherapy

Translational Biomedical Research


We evaluated the changes in CD4 + CD25high regulatory T (Treg) cells and FOXP3 mRNA expression in patients with advanced esophageal cancer as well as its clinical significance. For this purpose, the frequencies of peripheral blood Treg cells in 68 patients with advanced esophageal cancer and 40 healthy controls were determined by flow cytometry, and FOXP3 mRNA expression in Treg cells of 40 patients was determined by RT–PCR. The data show that Treg cell numbers were significantly higher (P < 0.01) in esophageal cancer patients (1.82 ± 0.54% of CD4 + T cells) as compared with healthy controls (1.52 ± 0.70% of CD4+ T cells). Treg cell numbers in the patients were significantly higher (P < 0.05) before chemotherapy (1.82 ± 0.54% of CD4 + T cells) than after chemotherapy (1.66 ± 0.58% of CD4 + T cells). Expression of the FOXP3 mRNA in the patients was significantly lower (P < 0.05) after chemotherapy (0.266 ± 0.028% of CD4 + T cells) than before chemotherapy (0.318 ± 0.027% of CD4 + T cells). It was, therefore, concluded that Treg cell numbers as well as FOXP3 mRNA expression in advanced esophageal cancer patients were significantly decreased after chemotherapy. Notably, FOXP3 gene may thus be involved in regulating the numbers and function of Treg cells in advanced esophageal cancer patients receiving chemotherapy.


Advanced esophageal cancer CD4 + CD25high regulatory T cells FOXP3 



The authors acknowledge the financial support provided by the Anhui Scientific Department (Grant # 06023090C) and the Natural Sciences Foundation of Anhui Province (Grant # 007413256X) for the authors also thank all the participants of the study for their participation and cooperation.


  1. 1.
    Paust, S., & Cantor, H. (2005). Regulatory T cells and autoimmune disease. Immunological Review, 204, 195–207.CrossRefGoogle Scholar
  2. 2.
    Takahashi, T., & Sakaguchi, S. (2003). The role of regulatory T cells in controlling immunologic self-tolerance. International Review of Cytology, 225, 1–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Terabe, M., & Berzofsky, J. A. (2004). Immunoregulatory T cells in tumor immunity. Current Opinion in Immunology, 16, 157–162.PubMedCrossRefGoogle Scholar
  4. 4.
    Wolf, A. M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., & Grubeck-Loebenstein, B. (2003). Increase of regulatory T cells in the peripheral blood of cancer patients. Clinical Cancer Research, 9, 606–612.PubMedGoogle Scholar
  5. 5.
    Hori, S., Nomura, T., & Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299, 1057–1061.PubMedCrossRefGoogle Scholar
  6. 6.
    Sakaguchi, S., & Powrie, F. (2007). Emerging challenges in regulatory T cell function and biology. Science, 317, 627–629.PubMedCrossRefGoogle Scholar
  7. 7.
    Lopes, J. E., Soper, D. M., & Ziegler, S. F. (2007). Foxp3 is required throughout the life of a regulatory T cell. Science STKE, 393, pe36.Google Scholar
  8. 8.
    Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003). CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer, 98, 1089–1099.PubMedCrossRefGoogle Scholar
  9. 9.
    Needham, D. J., Lee, J. X., & Bailharz, M. W. (2006). Intra-tumoral regulatory T cells: a potential new target in cancer immunotherapy. Biochemical and Biophysical Research Communications, 343, 684–691.PubMedCrossRefGoogle Scholar
  10. 10.
    Okita, R., Saeki, T., Takashima, S., Yamaguchi, Y., & Toge, T. (2005). CD4 + CD25 + regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncological Report, 14, 1269–1273.Google Scholar
  11. 11.
    Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H., & Fujii, H. (2003). Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clinical Cancer Research, 9, 4404–4408.PubMedGoogle Scholar
  12. 12.
    Zhang, L., Dermawan, K. T., Jin, M. L., Xiong, S. D., & Chu, Y. W. (2008). Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells? Medical Hypotheses, 71, 802–804.PubMedCrossRefGoogle Scholar
  13. 13.
    Martin, B., Banz, A., Bienvenu, B., et al. (2004). Suppression of CD4 + T lymphocyte effector functions by CD4 + CD25 + cells in vivo. The Journal of Immunology, 172, 3391–3398.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of OncologyAnhui Medical University Affiliated Anhui Provincial HospitalHefeiChina

Personalised recommendations